资料显示，北京神州细胞生物技术集团股份公司位于北京市北京经济技术开发区科创七街31号院，成立 日期2007年4月23日，上市日期2020年6月22日，公司主营业务涉及恶性肿瘤、自身免疫性疾病、感染性 疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。主营业务收入构成为：销售商品 100.00%。 神州细胞所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：抗癌治癌、创新 药、细胞治疗、抗癌药物、百度概念等。 截至9月30日，神州细胞股东户数1.37万，较上期增加40.96%；人均流通股32390股，较上期减少 29.06%。2025年1月-9月，神州细胞实现营业收入13.12亿元，同比减少32.27%；归母净利润-2.51亿元， 同比减少267.17%。 机构持仓方面，截止2025年9月30日，神州细胞十大流通股东中，香港中央结算有限公司位居第六大流 通股东，持股461.68万股，为新进股东。南方中证500ETF（510500）位居第七大流通股东，持股260.91 万股，相比上期减少9.34万股。创新药（159992）位居第十大流通股东，持股178.93万股，为新进股 东。中欧医疗健康 ...

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.44% on November 12, with significant gains from specific stocks, while the overall market indices showed a decline [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4000.14, down 0.07% - The Shenzhen Component Index closed at 13240.62, down 0.36% [1] Group 2: Top Gainers in Biopharmaceutical Sector - BGI Innovation (300318) led the gains with a closing price of 7.20, up 20.00% with a trading volume of 651,300 shares and a transaction value of 458 million yuan - Sanyuan Gene (920344) followed with a closing price of 33.15, up 12.45% and a trading volume of 85,300 shares [1] - Other notable gainers include: - Sangfor Biopharma (688336) at 68.50, up 6.60% - Sai Sheng Pharmaceutical (300485) at 12.88, up 4.63% [1] Group 3: Market Capital Flow - The biopharmaceutical sector saw a net inflow of 325 million yuan from institutional investors, while retail investors experienced a net outflow of 317 million yuan [2] - The top stocks by net inflow from institutional investors included: - Sangfor Biopharma (688336) with a net inflow of 136 million yuan - He Yuan Biopharma (688765) with a net inflow of 108 million yuan [3]

神州细胞所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、抗癌治 癌、抗癌药物、生物医药、细胞治疗等。 截至9月30日，神州细胞股东户数1.37万，较上期增加40.96%；人均流通股32390股，较上期减少 29.06%。2025年1月-9月，神州细胞实现营业收入13.12亿元，同比减少32.27%；归母净利润-2.51亿元， 同比减少267.17%。 机构持仓方面，截止2025年9月30日，神州细胞十大流通股东中，香港中央结算有限公司位居第六大流 通股东，持股461.68万股，为新进股东。南方中证500ETF（510500）位居第七大流通股东，持股260.91 万股，相比上期减少9.34万股。创新药（159992）位居第十大流通股东，持股178.93万股，为新进股 东。中欧医疗健康混合A（003095）退出十大流通股东之列。 责任编辑：小浪快报 11月10日，神州细胞盘中上涨2.00%，截至14:14，报50.91元/股，成交9873.93万元，换手率0.44%，总 市值226.72亿元。 资金流向方面，主力资金净流出432.43万元，特大单买入480.51万元，占比4.87%，卖 ...

Core Points - The company will hold a Q3 2025 earnings presentation on November 17, 2025, from 10:00 to 11:00 AM [2][4] - The presentation will be conducted in an online interactive format, allowing investors to engage and ask questions [3][5] - Investors can submit questions from November 10 to November 14, 2025, through the Shanghai Stock Exchange's roadshow center or via the company's email [2][5] Meeting Details - The meeting will take place on November 17, 2025, from 10:00 to 11:00 AM [4] - It will be held online via the Shanghai Stock Exchange's roadshow center [4][5] - Key participants include the company's Chairman and General Manager, Dr. Xie Liangzhi, and other senior executives [4] Investor Participation - Investors can join the earnings presentation online on the specified date and time [5] - Questions can be pre-submitted through the roadshow center or the company's email before the deadline [5] Contact Information - The contact department for inquiries is the Securities Department, reachable at 010-50812198 [6] - Additional inquiries can be directed to the company's email: ir@sinocelltech.com [7]

Core Viewpoint - The company, Beijing Sinocell Technology Group Co., Ltd., is set to hold a Q3 2025 earnings presentation on November 17, 2025, to discuss its operational results and financial status with investors [2][3][4]. Group 1: Meeting Details - The earnings presentation will take place on November 17, 2025, from 10:00 to 11:00 AM [4]. - The format of the meeting will be an online text interaction, hosted on the Shanghai Stock Exchange's roadshow center [4][5]. - Participants will include the company's Chairman and General Manager, Dr. Xie Liangzhi, along with other key executives [4]. Group 2: Investor Participation - Investors can participate in the earnings presentation by logging into the Shanghai Stock Exchange's roadshow center on the scheduled date [5]. - A pre-question submission period is available from November 10 to November 14, 2025, allowing investors to submit questions via the roadshow center or the company's email [5]. Group 3: Contact Information - The contact department for inquiries is the Securities Department, reachable at phone number 010-50812198 and email ir@sinocelltech.com [7].

投资者可于 2025 年 11 月 10 日（星期一）至 11 月 14 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinocelltech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 证券代码：688520 证券简称：神州细胞 公告编号：2025-041 北京神州细胞生物技术集团股份公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 线上文字互动平台：上海证券交易所上证路演中心（https://roadshow.ss einfo.com/） （三）线上文字互动平台：上海证券交易所上证路演中心（http://roadshow. sseinfo.com/） 三、参加人员 公司董事长兼总经理谢良志博士，董事、副总经理、董事会秘书唐黎明先生， 财务总监马洁女士，独立董事贾凌云女士（如有特殊情况，参会人员可能进行调 整）。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2025 ...

Group 1 - The core viewpoint of the article highlights a collective decline in the A-share market for innovative drug concept stocks, with significant drops in several companies [1] Group 2 - Changshan Pharmaceutical experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2] - Zicheng Pharmaceutical and Baiyang Pharmaceutical both fell by over 7%, with market capitalizations of 6.984 billion and 13.3 billion respectively, and year-to-date increases of 68.53% and 9.05% [2] - Other companies such as Bibete-U, Kangchen Pharmaceutical, and Kanghong Pharmaceutical saw declines exceeding 5%, with market capitalizations of 14.3 billion, 28.8 billion, and respective year-to-date increases of 79.30% and 62.53% [2] - The article also notes that MACD golden cross signals have formed, indicating potential upward momentum for some stocks [1]

Group 1 - Shenzhou Cell (688520.SH) reported its Q3 2025 results, with 17 institutional investors holding a total of 332 million shares, representing 74.53% of the company's total share capital [1] - The top ten institutional investors collectively hold 74.49% of the shares, with a slight decrease of 0.64 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely the Innovative Medicine fund, increased its holdings, while two funds, including Southern CSI 500 ETF and Galaxy Quantitative Preferred Mixed A, reduced their holdings [2] - Six new public funds were disclosed this period, including Qianhai Kaiyuan Refinance Stock and Zheshang Smart Selection Leading Three-Year Holding Period A [2] - A total of 258 public funds were not disclosed this period, including China Europe Medical Health Mixed A and China Merchants National Bio-Medical Index A [2]

Group 1 - The core viewpoint of the article highlights that Shenzhou Cell reported a significant decline in revenue and incurred losses in the third quarter of 2023 [1] - For the first three quarters of 2025, the company's revenue was approximately 1.312 billion yuan, representing a year-on-year decrease of 32.27% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 251 million yuan, with basic earnings per share reflecting a loss of 0.6 yuan [1] - As of the report, Shenzhou Cell's market capitalization stood at 23.6 billion yuan [1]

Core Viewpoint - Shenzhou Cell is a leading innovative biopharmaceutical company in China, focusing on the research and development of biological drugs across various therapeutic areas, including malignant tumors and autoimmune diseases [1] Group 1: Business Performance - For Q3 2025, Shenzhou Cell reported revenue of 1.312 billion yuan, ranking 10th among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was -251 million yuan, placing the company 31st in the industry, while the top performer, Tonghua Dongbao, achieved a net profit of 1.188 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Shenzhou Cell's debt-to-asset ratio was 101.46%, a decrease from 104.24% year-on-year, but still significantly higher than the industry average of 26.88%, indicating substantial debt pressure [3] - The gross profit margin for the same period was 94.09%, slightly down from 96.28% year-on-year, yet above the industry average of 70.17%, reflecting strong profitability potential [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 40.96% to 13,700, while the average number of circulating A-shares held per shareholder decreased by 29.06% to 32,400 [5] - Notable changes among the top ten circulating shareholders include the entry of Hong Kong Central Clearing Limited and the South China CSI 500 ETF, while the China Europe Medical Health Mixed A fund exited the list [5] Group 4: Market Outlook - According to West Securities, Shenzhou Cell's revenue in the first half of 2025 was below expectations due to price reductions from centralized procurement and medical insurance controls affecting its core product, Anjiah [6] - Despite challenges, the company is expected to see growth from new products and a stable increase in sales of other antibody drugs, with projected revenues for 2025-2027 of 2.194 billion, 2.543 billion, and 3.021 billion yuan, respectively [6] - Zhongyou Securities anticipates a revenue increase in 2024, with a forecast of 2.827 billion yuan for 2025, and a net profit of 223 million yuan, maintaining a "buy" rating [6]